Recent Posts
- Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
- Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
- Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
- Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
- Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
Recent Comments
No comments to show.